Home
Account
Research Tools & Data
Educate
Contribute
News
ETFs
Sectors
About
Subscribe
Login
Manage Account
Quote and Research
Stock Charts
Earnings Calendar
Technical Scans
Economic Calendar
Chart School
Tutorials
Learning Center
Submit Article
Join Blog Network
Chat Rooms
Rate Broker
Rate Software
About Us
Contact Us
Advertise With Us
Terms and Conditions
Enter Symbol
Overview
Community Research
Stock Sentiment
Whisper Estimates
Enter Estimates
Company Profile
Technical Charts
Competitors
Analyst Ratings
Analyst Estimates
Sales Estimates
Related News
Blog Articles
Press Releases
Message Board
Option Chain
Financial Ratios
Technicals
SEC Filings
Press Releases
BenchmarkJournal.Com Free Analyst Review for CMCSK, NVAX, ARUN, CREE, XTNT and CDNS
XTENT, Inc. Announces That It Has Postponed the Special Meeting of Its Stockholders
XTENT, Inc. Receives Conditional Approval for Investigational Device Exemption of Custom NX(R) Drug Eluting Stent System from United States Food and Drug Administration
XTENT, Inc. Announces Approval of Plan of Liquidation and Dissolution by Board of Directors and Filing of Proxy Materials With the SEC
XTENT Receives CE Mark Approval for CUSTOM NX (R) Drug-Eluting Stent System
XTENT Announces Fourth Quarter 2008 Financial Results and Business Progress
XTENT to Retain Investment Bank to Pursue Strategic Alternatives
XTENT Announces Third Quarter 2008 Financial Results
Custom NX(R) Drug Eluting Stent System Continues to Demonstrate Favorable Outcomes in Challenging Patient Populations at One, Two and Three Years
XTENT Announces Clinical Trial Data to be Presented at Annual Meeting of Transcatheter Cardiovascular Therapeutics Next Week
XTENT Announces CUSTOM II Data Selected for Publication in EuroIntervention
XTENT Announces Second Quarter 2008 Financial Results and Business Progress
XTENT Appoints Christopher M. Smith and Arthur T. Taylor to Board of Directors
XTENT Announces CUSTOM I Data Receives Recognition from EuroIntervention
XTENT Announces European Regulatory Update
XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting - Jun 2 2008 2:59AM
XTENT Announces Clinical Trial Data to be Presented at Annual EuroPCR Meeting Next Week - Jun 2 2008 2:59AM
XTENT Announces First Quarter 2008 Financial Results
Fundamental data is provided by
Zacks Investment Research
, market data is provided by
AlphaTrade.
, and Commentary and Press Releases provided by
Quotemedia
